Since treatment of blood clot with Warfarin may poses several dangerous adverse events, such as heavy bleeding complications, oral anticoagulant Dabigatran (Pradaxa from Boehringer Ingelheim) therefore which have 'the same benefits' become an alternative option, while it also doesn't require frequent blood test to monitor the extrinsic pathway of coagulation. However, ...
Dabigatran (marketed as Pradaxa in U.S., Europe and Australia, Pradax in Canada, and Prazaxa in Japan, from Boehringer Ingelheim) is an agent to prevent or reduce coagulation risk (prevent clotting risk of the blood) during thrombotic disorders medications. While this anticoagulation suspected able to compete with warfarin for that treatment, the ...